.png){kind=icon}
Return
Artificial intelligence in virtual screening: Models versus experiments
.png){kind=icon}
PRE
AI
DOI：10.1016/j.drudis.2022.05.013.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
A typical drug discovery project involves identifying active compounds with significant binding potential for selected disease-specific targets. Experimental high-throughput screening (HTS) is a traditional approach to drug discovery, but is expensive and time-consuming when dealing with huge chemical libraries with billions of compounds. The search space can be narrowed down with the use of reliable computational screening approaches. In this review, we focus on various machine-learning (ML) and deep-learning (DL)-based scoring functions developed for solving classification and ranking problems in drug discovery. We highlight studies in which ML and DL models were successfully deployed to identify lead compounds for which the experimental validations are available from bioassay studies.
Keywords:
Computational drug discovery
Scoring functions
Machine learning-based scoring
Binding affinity
Binding assay studies
Chemical spaces
Journal
IF:
7.5
Papers:
6.4K
Citations:
2.3W
Organization
Cited Papers
ShareSaveShareSaveShareSave
Fabrication and compatibility evaluation of polycaprolactone/hydroxyapatite/collagen-based fiber scaffold for anterior cruciate ligament injury.png)
RSC Advances
OAAI
RSC AdvancesIF0
OAAIShareSaveShareSave
View more